Vera Therapeutics, a leading biotechnology company specializing in severe immune conditions, reported favorable results after 72 weeks from the open-label extension (OLE) stage of its Phase 2b ORIGIN clinical trial of atacicept in patients with IgA nephropathy (IgAN). Prior to market opening on Nasdaq, Vera's stocks had increased by over 11 percent, trading at $18.90.
The compiled data after 72 weeks with atacicept corresponds to a genuine disease modifying profile in IgAN. Following the 36-week randomised, double-blind, placebo-controlled phase of the ORIGIN trial, all participants were eligible to receive a 150 mg dose of atacicept in the OLE. Out of a total of 116 randomised participants, 106 completed the 72 weeks.
The participants treated with atacicept for 72 weeks exhibited a 62 percent reduction in Gd-IgA1, a decrease in the proportion of participants with hematuria to 19 percent, and a 48 percent reduction in UPCR in the per-protocol (PP) analysis.
Marshall Fordyce, Vera Therapeutics' CEO, expressed his satisfaction at presenting the encouraging new data from the Phase 2b ORIGIN trial's OLE phase at their R&D Day in New York. The team is increasingly convinced that atacicept has the revolutionary potential to emerge as a disease-altering treatment for IgAN patients.
The company also revealed that the ongoing primary ORIGIN 3 trial is progressing as planned, and participant enrollment is anticipated to be concluded in the latter half of this year. For more health-related updates, visit the rttnews.com.